Join the Epkinly group to help and get support from people like you.
Epkinly News
Epkinly (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved Epkinly® (epcoritamab-bysp) for the treatment of adults wi...
FDA Approves Epkinly (epcoritamab-bysp) Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NORTH CHICAGO, Ill., May 19, 2023 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp), as the first and only ...
Further information
Related condition support groups
Diffuse Large B-Cell Lymphoma, B Cell Lymphoma, Follicular Lymphoma